Publications

Affymetrix® DMET™ Plus Products

The following publications and review articles demonstrate the importance and the utility of Affymetrix DMET Plus Products in pharmacogenomic studies, clinical research, and the development of personalized medicine. The uses described in these reference articles have not been approved or cleared by FDA.

Technology reviews


Identification of new drug-related biomarkers


Drug development and safety research

U.S. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix).


Genotype/phenotype databasing

UNC’s McCleod discusses ‘practical’ approach to bringing pharmacogenetics to all countries. *GenomeWeb Pharmacogenomics Reporter* (2010).

**Biomarkers in oncology**


*This study was supported by Affymetrix*